Maybe filing to renew the shelf triggered a quiet period, or, maybe something else is happening behind the scenes to have the same effect. We know that public companies have to play by a much stricter set of rules than private co's, and no doubt J&J/Janssen and their legal dept. have clearly explained to Dr. Scarlett what can be addressed and what can be said about all things involving IMET and the trials.
not as outraged as I feel about the current SP MM signals
Bid:4.77 x 100
Ask:4.97 x 500 (gap up)
Bid:2.76 x 500 (gap down)
Ask:3.22 x 100
why did Chippy go hide 2 weeks ago? He could have said all systems still a go. No he said nothing and then rushed to renew the shelf and mention an acquisition hidden in the 8K without yet booking the deposit from Janssen. SP is trading like the deal is off.
The DJIA chart started correcting Aug 18, 2015. Geron started dropping after Aug. 5, 2015 when the market didn't like his acquisition sneaky comment on the 8K. Superimpose both charts and it is clear as the deception going on here. Tutes have slowly pulled out.
This is the date that is nine months after the effective date of the Collaboration Agreement signed November 13, 2014.
This is on Page 15 of the 6/30/2015 10Q. "transfer of the know-how and intellectual property, including our obligation to procure supply for manufacturing imetelstat for up to nine months after the effective date of the Collaboration Agreement and transfer existing supplies of imetelstat drug to Janssen."
Reading this tells me that all revenue from Imetelstat after August 13, 2015 will go to Janssen. Janssen had 9 months to review all aspects of Imetelstat and had the right to not to go forward with the Clinical Trials but chose to go forward with the Clinical Trials. Gern's revenue going forward will come from Janssen.
What is next for Gern after infusion takes place. Gern can only comment on the Primary Outcome measures, NCT02426086.
1. Percentage of participants who achieve greater or equal to 35% reduction in spleen volume, 24 weeks.
2. Percentage of participants who achieve greater than or equal to 50% reduction in total system score, 24 weeks.
I think if Gern reaches this milestone, Janssen will take it from there.
the fact that the CEO
1.mentions planned acquisitions in the 8K on Aug 5th,
2. then cancels the following CC.
3.This when Jansen has after 4 months of officially registering the trial start in June has yet to recruit one patient for infusion in it's world wide phase ll MF trials. Another obvious delay from previous mid summer trial start date expectations
4. The delayed booking of $35mil upfront payment from Janssen for no apparent reason.
If this all doesn't add Fear, Uncertainty & Doubt in the minds of investors well then Donald Trump must have real hair on his shtick shifter
5. renews another shelf 2 months bfr the previous one expires
got a spare raft....we're sinking over here in GERN
Sentiment: Strong Buy
that article starts out with side effects. Boy do all the other approved cancer meds have no side effects like venous occulsions and heart damage, etc!
Sentiment: Strong Buy